Milena Perez Mak

1.8k total citations
34 papers, 664 citations indexed

About

Milena Perez Mak is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Milena Perez Mak has authored 34 papers receiving a total of 664 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 19 papers in Pulmonary and Respiratory Medicine and 11 papers in Surgery. Recurrent topics in Milena Perez Mak's work include Lung Cancer Treatments and Mutations (8 papers), Head and Neck Cancer Studies (8 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Milena Perez Mak is often cited by papers focused on Lung Cancer Treatments and Mutations (8 papers), Head and Neck Cancer Studies (8 papers) and Cancer Immunotherapy and Biomarkers (6 papers). Milena Perez Mak collaborates with scholars based in Brazil, United States and Japan. Milena Perez Mak's co-authors include William N. William, Lixia Diao, Kevin R. Coombes, Pan Tong, John N. Weinstein, John V. Heymach, Jaime Rodriguez‐Canales, Ignacio I. Wistuba, Don L. Gibbons and Ferdinandos Skoulidis and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Clinical Cancer Research.

In The Last Decade

Milena Perez Mak

31 papers receiving 657 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Milena Perez Mak Brazil 12 399 234 189 137 108 34 664
E. del Barco Spain 17 341 0.9× 260 1.1× 145 0.8× 118 0.9× 34 0.3× 66 629
Yabing Cao China 15 350 0.9× 135 0.6× 191 1.0× 132 1.0× 144 1.3× 52 811
L.L. Siu Canada 10 833 2.1× 290 1.2× 248 1.3× 83 0.6× 179 1.7× 30 1.1k
Saurabh Zanwar United States 11 225 0.6× 102 0.4× 187 1.0× 35 0.3× 42 0.4× 69 504
Yongrui Bai China 14 278 0.7× 244 1.0× 181 1.0× 143 1.0× 90 0.8× 49 739
Feng Wen China 14 218 0.5× 206 0.9× 131 0.7× 102 0.7× 79 0.7× 53 699
Robert R. Carroll United States 10 705 1.8× 184 0.8× 73 0.4× 81 0.6× 43 0.4× 14 894
Huabin Hu China 14 491 1.2× 203 0.9× 156 0.8× 88 0.6× 95 0.9× 68 751
Xiao-Jing Du China 8 497 1.2× 194 0.8× 67 0.4× 60 0.4× 103 1.0× 9 677
Giulia Baciarello France 15 326 0.8× 272 1.2× 92 0.5× 114 0.8× 53 0.5× 40 572

Countries citing papers authored by Milena Perez Mak

Since Specialization
Citations

This map shows the geographic impact of Milena Perez Mak's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Milena Perez Mak with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Milena Perez Mak more than expected).

Fields of papers citing papers by Milena Perez Mak

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Milena Perez Mak. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Milena Perez Mak. The network helps show where Milena Perez Mak may publish in the future.

Co-authorship network of co-authors of Milena Perez Mak

This figure shows the co-authorship network connecting the top 25 collaborators of Milena Perez Mak. A scholar is included among the top collaborators of Milena Perez Mak based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Milena Perez Mak. Milena Perez Mak is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Paglioni, Mariana de Pauli, Ana Gabriela Costa Normando, Aline Lauda Freitas Chaves, et al.. (2025). Preoperative neoadjuvant chemotherapy or immunotherapy in head and neck cancer: A systematic review and meta-analysis of surgical risk and pathologic response. Critical Reviews in Oncology/Hematology. 212. 104742–104742. 2 indexed citations
2.
Rivera, César, Xaviera A. López-Cortés, Milena Perez Mak, et al.. (2024). Prospective Cohort Study Identifies Medical Predictors of Treatment-Related Oral Toxicities in Oral and Oropharyngeal Cancer Patients. Dentistry Journal. 12(4). 89–89. 1 indexed citations
3.
Gray, Jhanelle E., Michael Schenker, Mehmet Alı Nahıt Şendur, et al.. (2024). The Phase 3 KEYLYNK-006 Study of Pembrolizumab Plus Olaparib Versus Pembrolizumab Plus Pemetrexed as Maintenance Therapy for Metastatic Nonsquamous NSCLC. Journal of Thoracic Oncology. 20(2). 219–232. 6 indexed citations
4.
Oliveira, Thiago Bueno de, T. Motta, Andrea Juliana Gomes, et al.. (2023). A single-arm, multi-institutional, phase 2 study of a pembrolizumab-based organ preservation strategy for locally advanced larynx cancers: SMART-KEY (LACOG 0720) trial.. Journal of Clinical Oncology. 41(16_suppl). TPS6111–TPS6111.
5.
Goto, Keiko, Benjamin Solomon, K. Park, et al.. (2023). LBA4 Randomized phase III study of first-line selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive NSCLC. Annals of Oncology. 34. S1303–S1303. 4 indexed citations
6.
Ribeiro, Ana Carolina Prado, Thaís Bianca Brandão, César Rivera, et al.. (2022). Patient's perceptions of oral and oropharyngeal cancer diagnosis disclosure: communication aspects based on SPIKES protocol. Oral Surgery Oral Medicine Oral Pathology and Oral Radiology. 135(4). 518–529. 4 indexed citations
7.
Argiris, Athanassios, Kevin J. Harrington, Makoto Tahara, et al.. (2021). LBA36 Nivolumab (N) + ipilimumab (I) vs EXTREME as first-line (1L) treatment (tx) for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Final results of CheckMate 651. Annals of Oncology. 32. S1310–S1311. 21 indexed citations
8.
Moniz, Camila Motta Venchiarutti, et al.. (2020). Managing oncology clinical trials during COVID-19 pandemic. Contemporary Clinical Trials Communications. 19. 100637–100637. 15 indexed citations
9.
Mak, Milena Perez, Fátima Solange Pasini, Lixia Diao, et al.. (2020). Valproic acid combined with cisplatin-based chemoradiation in locally advanced head and neck squamous cell carcinoma patients and associated biomarkers. ecancermedicalscience. 14. 1155–1155. 10 indexed citations
10.
Caparica, Rafael, Alain Hendlisz, Evandro de Azambuja, et al.. (2020). Malignant bowel obstruction: effectiveness and safety of systemic chemotherapy. BMJ Supportive & Palliative Care. 14(e2). e1882–e1888. 3 indexed citations
11.
Hoff, Paulo M., et al.. (2018). Palliative chemotherapy outcomes in patients with ECOG-PS higher than 1. ecancermedicalscience. 12. 831–831. 21 indexed citations
12.
Mak, Milena Perez, et al.. (2017). Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer: A Retrospective Analysis. Journal of Global Oncology. 4(4). 1–7. 5 indexed citations
13.
Mak, Milena Perez, Fátima Solange Pasini, Lixia Diao, et al.. (2017). Phase II trial of valproic acid combined with cisplatin-based chemoradiation in locally advanced (LA) head and neck squamous cell carcinoma (HNSCC) patients (pts).. Journal of Clinical Oncology. 35(15_suppl). e17546–e17546.
14.
Mak, Milena Perez & William N. William. (2014). Targeting the epidermal growth factor receptor for head and neck cancer chemoprevention. Oral Oncology. 50(10). 918–923. 21 indexed citations
15.
Mak, Milena Perez & Bonnie S. Glisson. (2014). Is there still a role for induction chemotherapy in locally advanced head and neck cancer?. Current Opinion in Oncology. 26(3). 247–251. 9 indexed citations
16.
Mak, Milena Perez, et al.. (2014). Advanced small-cell ovarian carcinoma, hypercalcemic type: a challenging therapeutic entity. Autopsy and Case Reports. 4(3). 47–52. 3 indexed citations
17.
Mak, Milena Perez, Francisco César Carnevale, Airton Mota Moreira, et al.. (2013). Percutaneous Transhepatic Biliary Drainage in Patients with Advanced Solid Malignancies: Prognostic Factors and Clinical Outcomes. Journal of Gastrointestinal Cancer. 44(4). 398–403. 28 indexed citations
18.
Guindalini, Rodrigo Santa Cruz, et al.. (2013). Multiagent chemotherapy for metastatic adenocarcinoma of the seminal vesicle. Anti-Cancer Drugs. 25(1). 115–119. 4 indexed citations
19.
Mak, Milena Perez, Verônica T. Costa e Silva, Regina Matsunaga Martin, et al.. (2012). Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition. Supportive Care in Cancer. 20(9). 2195–2197. 32 indexed citations
20.
Ferrarotto, Renata, Karime Kalil Machado, Milena Perez Mak, et al.. (2012). A multicenter, multinational analysis of mitomycin C in refractory metastatic colorectal cancer. European Journal of Cancer. 48(6). 820–826. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E. del Barco Breakdown of academic impact, for papers by Yabing Cao Breakdown of academic impact, for papers by L.L. Siu Breakdown of academic impact, for papers by Saurabh Zanwar Breakdown of academic impact, for papers by Yongrui Bai Breakdown of academic impact, for papers by Feng Wen Breakdown of academic impact, for papers by Robert R. Carroll Breakdown of academic impact, for papers by Huabin Hu Breakdown of academic impact, for papers by Xiao-Jing Du Breakdown of academic impact, for papers by Giulia Baciarello
Rankless by CCL
2026